Dihexa is a small, orally active oligopeptide derived from angiotensin IV, developed at Washington State University and studied for cognition and Alzheimer's disease.
Dihexa Prices
10 vendors · 4 with an issuer-verified COA · lowest 10mg from $38.70 · checked
Where to buy Dihexa: 10 vendors compared
| Vendor | Price | Actions |
|---|---|---|
| $38.70 | Buy Dihexa from Ararat Peptides | |
| $42.00 | Buy Dihexa from Essential Research Labs | |
| $42.0010mg packageChecked today | Buy Dihexa from Pure Peptides | |
| 1-test panelVerified COAILS Laboratories | $44.99 | Buy Dihexa from Amino Club |
| 4-test panelVerified COAHorizon Analytical · Tested Aug 6, 2026 | $57.59 | Buy Dihexa from Summit Research Supply |
| 2-test panelVerified COAHorizon Analytical · Tested Aug 6, 2026 | $71.9910mg packageChecked today | Buy Dihexa from Northline Labs |
| 6-test panelVerified COABioSyn Systems · Tested Jul 6, 2026 | $79.19 | Buy Dihexa from Cenexa Labs |
| $100.45 | Buy Dihexa from Atlas Longevity | |
| $129.995% off via our link·auto10mg packageChecked today | Buy Dihexa from Licensed Peptides | |
| $252.00 | Buy Dihexa from American Peptides |
Tracked every day
Dihexa listing prices, tracked daily
The five cheapest in-stock package prices for Dihexa on each collected day, and the vendors that most often held those places.
Five cheapest in-stock package prices per day
Listed package price before coupons, any vial size. This is not the coupon-adjusted lowest 10mg price used to rank the comparison.
- Cheapest$42.00
- 2nd cheapest$43.00
- 3rd cheapest$59.99
- 4th cheapest$63.99
- 5th cheapest$71.99
Vendors most often in the cheapest five
- Northline Labs21 days$71.99-10.0%
- Amino Club16 days$59.990.0%
- American Peptides15 days$140.00last seen Oct 7, 20260.0%
- Licensed Peptides13 days$129.99last seen Oct 7, 20260.0%
- Essential Research Labs8 days$60.00last seen Sep 26, 20260.0%
- Cenexa Labs7 days$98.99last seen Oct 7, 20260.0%
- Elytra Labs6 days$40.00last seen Sep 24, 20260.0%
- Pure Peptides3 days$42.000.0%
Top 8 of 11 vendors that reached the cheapest five
Current market data
Dihexa Price Report
A current summary of public listings after the price comparison above. Shipping and tax are not included.
The lowest current 10mg cost for Dihexa is $38.70 from Ararat Peptides. The median across vendors is $64.79.
- Lowest 10mg cost
- $38.70Ararat Peptides
- Median 10mg cost
- $64.79One normalized offer per vendor
- Lowest package total
- $38.70Ararat Peptides · package size may differ
- Public COA coverage
- 90%9 of 10 vendors
What the market shows
PeptidePrices found 11 in-stock listings from 10 vendors, checked through Oct 10, 2026. The lowest 10mg cost is 40% below the vendor median of $64.79; 5 vendors (50%) fall below that median. 9 of 10 vendors (90%) publish public COA evidence.
A public COA link shows that a vendor publishes testing data. It does not prove that every listed vial has a matching current report. Match the product, strength, batch, and lot before relying on a report.
How this report is calculated
The headline and median use each vendor's lowest whole-package checkout cost to obtain at least 10mg. Smaller packages are multiplied until the target is met, while larger packages retain their full checkout price. The lowest package total is shown only as secondary context because package sizes differ. Known public coupon discounts are applied. Shipping, tax, and unverified promotions are excluded.
Research context
What is Dihexa? Research, safety, and status
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic oligopeptide engineered from angiotensin IV to enhance cognition by building new synaptic connections. It was developed at Washington State University as a candidate for Alzheimer's disease and other conditions involving cognitive decline, and is notable for crossing the blood-brain barrier and being active orally.
All of its evidence is preclinical, animal and cell studies. There are no human clinical trials, it is not FDA-approved, and it is sold for laboratory research only. Everything below is research context, not medical guidance.
Key research takeaways
Its proposed mechanism is potentiating hepatocyte growth factor (HGF) at the c-Met receptor to drive synaptogenesis, the formation of new synaptic connections.
The headline claim, that it is roughly 10 million times (7 orders of magnitude) more potent than BDNF at promoting synapse formation, comes from a 2014 in-vitro assay (Harding et al.) and should be read as a cell-based potency figure, not a clinical outcome.
All evidence is preclinical; it is not FDA-approved, and a theoretical cancer concern (c-Met activation) is the key open safety question.
Dihexa at a glance
PeptidePrices safety rating
4/10 · Not FDA-approved
Mechanism
HGF/MET system potentiator; derived from angiotensin IV; binds hepatocyte growth factor (HGF) and prevents its degradation; activates MET receptor; promotes synaptogenesis, dendritic spine density, and neuroplasticity; ~7 orders of magnitude more potent than BDNF per unit.
Research areas
Cognitive enhancement (one of the most potent nootropics known); Alzheimer's and dementia research; traumatic brain injury recovery; synaptogenesis; memory and learning enhancement; neurogenesis.
Regulatory / research status
Research / preclinical only
Half-life
~24 hours (estimated).
Storage
Store at room temperature; refrigerate after opening for extended shelf life.
Reported side effects
Limited human data. Theoretical cancer concern (HGF/MET pathway implicated in tumor growth, use with caution in cancer history).
Acts via c-Met activation, a tumor-growth pathway, giving a real oncogenicity concern; no long-term or human safety data; no human trials. Generally avoided with any cancer history. Safety ratings summarize published clinical data, adverse-event reporting, and regulatory status. How PeptidePrices rates evidence. Research information only, not medical advice.
Study highlights
- Dihexa is an orally active, blood-brain-barrier-permeable angiotensin IV analogue that potentiates hepatocyte growth factor (HGF) signaling at the c-Met receptor; the original 2014 JPET paper (PMID 25187433) reported it induced hippocampal spinogenesis and synaptogenesis orders of magnitude more potently than BDNF, however, this paper was formally retracted in April 2025 (PMID 40312093) due to data integrity concerns, and its primary findings should not be cited as established.
- A 2021 Brain Sciences study independent of the retracted group found that Dihexa treatment improved spatial learning and memory in APP/PS1 Alzheimer's model mice, reduced neuroinflammatory markers, and restored neuronal populations; the beneficial effects were blocked by PI3K/AKT pathway inhibitors, identifying this axis as the operative downstream mechanism.
- A 2018 systematic review of 32 experimental studies confirmed that angiotensin IV and its analogues broadly improved spatial working memory and passive avoidance tasks across animal models of cognitive impairment, with beneficial effects most pronounced when administered centrally near the time of learning.
- The retraction of the foundational 2014 paper necessitates caution: while independent animal studies suggest pro-cognitive effects remain plausible via HGF/c-Met and PI3K/AKT pathways, no human clinical trials have been conducted and the compound's safety and efficacy in humans are entirely unestablished.
Selected references
- Procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on HGF/c-met system [RETRACTED 2025] · J Pharmacol Exp Ther, 2014
- Retraction notice for PMID 25187433 · J Pharmacol Exp Ther, 2025
- Dihexa Rescues Cognitive Impairment and Recovers Memory in APP/PS1 Mice via PI3K/AKT Signaling · Brain Sci, 2021
- Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies · Neurosci Biobehav Rev, 2018
- Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats · J Huntingtons Dis, 2024
Related pages